Edited by: Marc Humbert
The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective
Version of Record online: 10 FEB 2010
© 2010 John Wiley & Sons A/S
Volume 65, Issue 9, pages 1141–1148, September 2010
How to Cite
Campbell, J. D., Spackman, D. E. and Sullivan, S. D. (2010), The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy, 65: 1141–1148. doi: 10.1111/j.1398-9995.2010.02336.x
- Issue online: 4 AUG 2010
- Version of Record online: 10 FEB 2010
- Accepted for publication 05 January 2010
- health economics;
- Markov model;
To cite this article: Campbell JD, Spackman DE, Sullivan SD. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy 2010; 65: 1141–1148.
Background: Omalizumab, an anti-immunoglobulin E antibody, reduces exacerbations and symptoms in uncontrolled allergic asthma. The study objective was to estimate the costs and consequences of omalizumab compared to usual care from a US payer perspective.
Methods: We estimated payer costs, quality-adjusted survival (QALYs), and the incremental cost-effectiveness ratio (ICER) of omalizumab compared to usual care using a state-transition simulation model that included sensitivity analyses. Every 2 weeks, patients could transition between chronic asthma and exacerbation health states. The best available evidence informed the clinical and cost input estimates. Five years of omalizumab treatment followed by usual care was assumed to estimate a lifetime horizon. Omalizumab responders (60.5% of treated) were modeled as a separate scenario where nonresponders reverted back to usual care after 16 weeks of active treatment.
Results: The mean lifetime discounted costs and QALYs were $83 400 and 13.87 for usual care and $174 500 and 14.19 for omalizumab plus usual care resulting in $287 200/QALY (95% interval: $219 300, $557 900). The ICER was $172 300/QALY when comparing omalizumab to usual care in the responder scenario. One-way sensitivity analyses indicated that the results were sensitive to the difference in treatment-specific utilities for the chronic state, exacerbation-associated mortality, omalizumab price, exacerbation rates, and response definition.
Conclusions: The results suggest that adding omalizumab to usual care improves QALYs at an increase in direct medical costs. The cost-effectiveness of omalizumab is similar to other chronic disease biologics. The value increases when omalizumab response is used to guide long-term treatment.